Scholarlink

Objectives <p>To assess the diagnostic performance, predictors, and clinical utility of MRI-guided prostate biopsy over an 18&#xa0;year period in a real-world tertiary care setting.</p> Materials and methods <p>We retrospectively analyzed patients who underwent MRI-guided prostate biopsy between 2006 and 2024 at a German tertiary care center. Clinical data, PI-RADS, PSA levels, prostate volume, and biopsy outcomes were evaluated. Logistic regression models assessed associations between clinical variables and cancer detection, clinical significance (ISUP ≥ 3), and upgrading after radical prostatectomy (RPE).</p> Results <p>Among 496 patients (mean age 66 ± 8&#xa0;years; PSA, median (IQR): 7.2&#xa0;ng/ml (5–10)), cancer was detected in 33% (162/496), with 29% (47/162) classified as clinically significant. In our biopsy cohort (PI-RADS 3: 12.7%, PI-RADS 4: 43.0%, PI-RADS 5: 5.6%), clinically significant prostate cancer (ISUP ≥ 3) was detected in 3.2% of PI-RADS 3, 12.2% of PI-RADS 4, and 28.6% of PI-RADS 5 lesions. PI-RADS 5 lesions were strongly associated with cancer detection (OR 3.6, 95% CI 1.35–10.13) and significant disease (OR 7.1, 95% CI 1.38–55.15), independent of age, prostate volume, and biopsy extent. While these covariates predicted overall biopsy positivity (<i>p</i> &lt; 0.02), they were not associated with significant cancer (<i>p</i> &gt; 0.05) or upgrading at RPE (<i>p</i> &gt; 0.05). Among 29 RPE patients, only one was upgraded. Post-biopsy CT was performed in all patients:&#xa0;MRI-guided biopsy was associated with a low complication rate: minor localized bleeding occurred in 4.4% of cases, and no major adverse events were observed.</p> Conclusions <p>MRI-guided prostate biopsy showed high diagnostic accuracy and safety in routine care. PI-RADS was the key predictor of clinically significant cancer. The low rate of upgrading after RPE supports its reliability in guiding patient management and avoiding overtreatment.</p> Clinical relevance statement <p>MRI-guided prostate biopsy enables accurate detection of clinically significant prostate cancer with low risk of understaging, supporting its routine use in personalized urologic oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transgluteal MRI in-bore prostate biopsy in routine clinical practice: a contemporary-cohort-study from a german tertiary center

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月2日

查看全文
  • Thomas Vogl,
  • Maximilian Holzer,
  • Scherwin Mahmoudi,
  • Leon Grünewald,
  • Vitali Koch,
  • Jennifer Gotta,
  • Philipp Reschke,
  • Mike Wenzel,
  • Benedikt Hoeh,
  • Philipp Mandel,
  • Felix Chun,
  • Jens Köllermann,
  • Boris Bodelle,
  • Simon Martin,
  • Jan-Erik Scholtz,
  • Renate Hammerstingl,
  • Tatjana Gruber-Rouh,
  • Katrin Eichler,
  • Peter Wild,
  • Simon Bernatz

摘要

Objectives

To assess the diagnostic performance, predictors, and clinical utility of MRI-guided prostate biopsy over an 18 year period in a real-world tertiary care setting.

Materials and methods

We retrospectively analyzed patients who underwent MRI-guided prostate biopsy between 2006 and 2024 at a German tertiary care center. Clinical data, PI-RADS, PSA levels, prostate volume, and biopsy outcomes were evaluated. Logistic regression models assessed associations between clinical variables and cancer detection, clinical significance (ISUP ≥ 3), and upgrading after radical prostatectomy (RPE).

Results

Among 496 patients (mean age 66 ± 8 years; PSA, median (IQR): 7.2 ng/ml (5–10)), cancer was detected in 33% (162/496), with 29% (47/162) classified as clinically significant. In our biopsy cohort (PI-RADS 3: 12.7%, PI-RADS 4: 43.0%, PI-RADS 5: 5.6%), clinically significant prostate cancer (ISUP ≥ 3) was detected in 3.2% of PI-RADS 3, 12.2% of PI-RADS 4, and 28.6% of PI-RADS 5 lesions. PI-RADS 5 lesions were strongly associated with cancer detection (OR 3.6, 95% CI 1.35–10.13) and significant disease (OR 7.1, 95% CI 1.38–55.15), independent of age, prostate volume, and biopsy extent. While these covariates predicted overall biopsy positivity (p < 0.02), they were not associated with significant cancer (p > 0.05) or upgrading at RPE (p > 0.05). Among 29 RPE patients, only one was upgraded. Post-biopsy CT was performed in all patients: MRI-guided biopsy was associated with a low complication rate: minor localized bleeding occurred in 4.4% of cases, and no major adverse events were observed.

Conclusions

MRI-guided prostate biopsy showed high diagnostic accuracy and safety in routine care. PI-RADS was the key predictor of clinically significant cancer. The low rate of upgrading after RPE supports its reliability in guiding patient management and avoiding overtreatment.

Clinical relevance statement

MRI-guided prostate biopsy enables accurate detection of clinically significant prostate cancer with low risk of understaging, supporting its routine use in personalized urologic oncology.